home All News open_in_new Full Article

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy versus placebo.1 Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity) but […]


today 8 d. ago attach_file Events

attach_file Events
attach_file Events
attach_file Other
attach_file Culture
attach_file Events
attach_file Other
attach_file Other
attach_file Economics
attach_file Science
attach_file Economics
attach_file Culture
attach_file Other
attach_file Other
attach_file Sport
attach_file Economics
attach_file Culture
attach_file Other
attach_file Events
attach_file Events
attach_file Society


ID: 3286961507
Add Watch Country

arrow_drop_down